8. Physiological Active Substances
17-AAG [17-(Allylamino)-17-desmethoxygeldanamycin; Allylaminogeldanamycin]
Wako Cat. No. 012-20101 (1 mg) <for Cellbiology>
Keep at -20℃
Potent, less toxic derivative of geldanamycin. Inhibits the essential ATPase activity of HSP90. apoptosis with antitumor activity.
Keep at -20℃
Potent, less toxic derivative of geldanamycin. Inhibits the essential ATPase activity of HSP90. apoptosis with antitumor activity.
| Appearance: | Red ~ dark purple, crystalline powder ~ powder |
| Solubility: | Soluble in DMSO (10mg/mL) or methanol (10mg/mL) |
[References]
1) Zhou, P, et al.: "ErbB2 degradation mediated by the co-chaperone protein CHIP", J. Biol.
Chem., 278, 13829-37 (2003)
2) Villa, R. et al.: "Inhibition of telomerase activity by geldanamycin and 17-allylamino,
17-demethoxygeldanamycin in human melanoma cells", Carcinogenesis, 24, 851-9 (2003)
3) Vasilevskaya, I. A., et al.: "Geldanamycin and its 17-allylamino-17-demethoxy analogue
antagonize the action of Cisplatin in human colon adenocarcinoma cells: diff erential caspase
activation as a basis for interaction", Cancer Res., 63, 3241-6 (2003)
4) Kamal, A., et al.: "A high-affi nity conformation of Hsp90 confers tumour selectivity on Hsp90
inhibitors", Nature, 425, 407-10 (2003)
ADP Ribosyltransferase C3, from Clostridium botulinum
Wako Cat. No. 011-14441 (10 µg) <for Biochemistry>
Keep at -20℃
Neurotoxin; Botulinum neurotoxin C3 with no toxicity
Keep at -20℃
Neurotoxin; Botulinum neurotoxin C3 with no toxicity
| Source: | Clostridium botulinum |
| Appearance: | Lyophilized |
| Solubility: | Soluble in ethanol, methanol and acetone. |
| Principle: | P2 fraction + [a-32P]NAD →ADP-ribosyltransferase C3→ [32P]ADP-rebose-P2 fraction + Nicotinamide |
| Activity: | Approximately 1 pmol/mg P2/ug C3 |
| Unit Defi nition: | An amount of ADP-ribose required for the formation of substrate (P2 fraction) 1 mg by 1 ug of ADP-ribosyltransferase C3 |
[References]
1) Ohashi, Y. and Narumiya, S.: "ADP-ribosylation of a Mr 21,000 membrane protein by type D botulinum toxin", J. Biol. Chem., 262, 1430-3 (1987)
2) Morii, M. et al.: "Immunochemical identifi cation of the ADP-ribosyltransferase in botulinum C1 neurotoxin as C3 exoenzyme-like molecule", J.
Biochem., 107, 769-75 (1990)
3) Narumiya, S., et al.: "Subcellular distribution and isoelectric heterogeneity of the substrate for ADP-ribosyl transferase from Clostridium botulinum",
Biochem. Biophys. Res. Commun., 150, 1122-30 (1988)
Antibiotics/Folate Metabolism related Substances
Ampicillin
[Anhydrous] Wako Cat. No. 017-10381 (5 g); 015-10382 (25 g)<for Biochemistry>
[Standard; anhydrous] Wako Cat. No. 017-20531 (200 mg) <for HPLC>
[Sodium Salt] Wako Cat. No. 010-10371 (5 g); 016-10373 (10 g); 018-10372 (25 g)<for Biochemistry>
Keep at -20℃
Antibiotics/Folate Metabolism related Substances An antibiotic which is a synthetic penicillin used in studies on dysentery and urinary tract infections.
It has a broad antibacterial spectrum and is active against Gram-positive and Gram-negative bacteria. It is also used for checking one of the properties of Ames test strain, i.e. the existence of drug resistance factor plasmid PKM101.
Keep at -20℃
Antibiotics/Folate Metabolism related Substances An antibiotic which is a synthetic penicillin used in studies on dysentery and urinary tract infections.
It has a broad antibacterial spectrum and is active against Gram-positive and Gram-negative bacteria. It is also used for checking one of the properties of Ames test strain, i.e. the existence of drug resistance factor plasmid PKM101.
| Appearance: |
[Anhydrous & the standard] White ~ slightly yellow, powder [Na Salt] White, crystalline powder ~ powder |
|
Assay (HPLC): [Anhydrous] 96.0+%; [Anhydrous standared] 98+% Potency (calculated on the dehydrous basis): [Sodium Salt] 850+ug/mg |
|
| Solubility: |
[Anhydrous] Soluble in MeOH or water. Slightly soluble in EtOH. Practically insoluble in ether. [Na Salt] Freely soluble in water. Sparingly soluble in EtOH. |
Wako Product Update Bio-No.1 [ page. 24 ]
Related Wako Products:
- TFAP:
leaflet









